Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Patent Profiles
-
By Kwame Mensah — Geron Corporation recently announced that it had been granted U.S. Patent No. 7,326,572, entitled "Endoderm cells from human embryonic stem cells." The ‘572 patent covers a method for producing endoderm cells from human embryonic stem cells (hESCs). The production of endoderm cells is a critical step in generating pancreatic…
-
By Donald Zuhn — Senomyx, Inc. announced last week that it has been granted five U.S. patents directed to human umami and sweet taste receptors. The patents are U.S. Patent Nos. 7,294,474; 7,297,543; 7,297,772; 7,301,009; and 7,309,577. With the addition of the five new patents, the San Diego-based company, which uses proprietary taste…
-
By Kwame Mensah — PuriCore recently announced that it had been granted U.S. Patent No. 7,276,255, entitled "Wound and Ulcer Treatment with Super-Oxidized Water." The ‘255 patent covers methods of treating an open wound with hypochlorous acid solutions at neutral or near-neutral pH. The method includes two processes: reducing wound bioburden and promoting…
-
By Donald Zuhn — Proteologics, Inc. announced today that it has been granted U.S. Patent No. 7,268,227. The ‘227 patent is the second U.S. patent to be awarded to the Rehovot, Israel-based biopharmaceutical company. According to the statement released by Proteologics, the ‘227 patent encompasses siRNA molecules that inhibit the expression of the…
-
By Kwame Mensah — Last November, Cyplasin Biomedical Ltd. announced that it had been granted U.S. Patent No. 7,271,242, entitled "Cytotoxic Cyplasin of the SeaHare, Aplysia punctata, cDNA Cloning and Expression of Bioreactive Recombinants." The ‘242 patent covers the production of cytotoxic cyplasin by mammalian cells and the use of this protein for…
-
By Donald Zuhn — Last month, stART Licensing, Inc. announced that it had been granted U.S. Patent Nos. 7,304,204 and 7,307,198. stART Licensing, Inc., an Austin, Texas-based joint venture between Geron Corp. and Exeter Life Sciences, Inc., manages and licenses a portfolio of patent rights related to animal reproductive technologies (including patents encompassing…
-
By Suresh Pillai — Last month, Morphotek, Inc., a subsidiary of Eisai Co., Ltd. based in Exton, Pennsylvania, announced that it had been granted U.S. Patent No. 7,235,643 ("Antibodies and methods for generating genetically altered antibodies with high affinity," issued June 26, 2007). This is the eleventh U.S. Patent awarded to Morphotek, Inc.…
-
By Donald Zuhn — Last Friday, Vaccinex, Inc. announced that it had been granted European Patent No. 1 340 088. According to the statement released by Vaccinex, the ‘088 patent covers the Rochester, New York-based company’s ActivMAb® antibody discovery technology platform, which can be used for the discovery and development of new monoclonal…
-
By Suresh Pillai — Metagenics, Inc. of San Clemente, California has been awarded U.S. Patent Nos. 7,270,835 ("Compositions that treat or inhibit pathological conditions associated with inflammatory response," issued September 18, 2007); 7,195,785 ("Complex mixtures exhibiting selective inhibition of cyclooxygenase-2," issued March 27, 2007) and 7,205,151 (same title, issued April 17, 2007), three…
-
By Donald Zuhn — Last week, Avicena Group, Inc. announced that it had been granted U.S. Patent No. 7,285,573. The ‘573 patent, which relates to use of creatine (lower left) and creatine phosphate (lower right) for treating amyotropic lateral sclerosis (ALS) or "Lou Gehrig’s Disease," is the fifth U.S. patent to be awarded…
Patent Docs 